Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Inhibition of tyrosine kinase pathways represents a potent and promising therapeutic approach, and in future could become a mainstay of therapy for patients with autoimmune and inflammatory ...

Signal binding to membrane receptor tyrosine kinases (RTKs) activates an enzyme called a kinase. Learn how kinases initiate a signaling cascade that relays information to the nucleus.

"Insulin binding to InsRα derepresses the tyrosine kinase activity of the β-subunit (InsRβ). This initiates a whole metabolic pathway with different steps that eventually allow glucose ...

The PKCβ and PI3K–Akt pathways are frequently activated in ... In addition, the receptor tyrosine kinase inhibitor and anti-angiogenic agent Sorafenib only partially inhibits the growth of ...

Tyrosine kinase inhibitors (TKIs ... TKIs target intracellular pathways, providing a complementary mechanism of action. Sustained-release TKI implants have demonstrated extended durability ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...